Montag & Caldwell LLC Has $1.12 Million Stock Position in Humana Inc. (NYSE:HUM)

Montag & Caldwell LLC lessened its stake in Humana Inc. (NYSE:HUM) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,450 shares of the insurance provider’s stock after selling 86 shares during the quarter. Montag & Caldwell LLC’s holdings in Humana were worth $1,122,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Rakuten Securities Inc. bought a new position in Humana during the 4th quarter worth $25,000. Gradient Investments LLC lifted its stake in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 40 shares during the period. Cetera Trust Company N.A bought a new stake in Humana in the fourth quarter worth approximately $28,000. Nvwm LLC increased its holdings in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in shares of Humana during the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Down 0.5 %

NYSE HUM traded down $1.51 during mid-day trading on Monday, reaching $304.39. 402,182 shares of the stock were exchanged, compared to its average volume of 1,975,062. The stock has a market capitalization of $36.68 billion, a PE ratio of 19.01, a PEG ratio of 1.79 and a beta of 0.45. The business’s fifty day simple moving average is $327.77 and its 200 day simple moving average is $393.91. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the firm posted $9.38 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. On average, research analysts anticipate that Humana Inc. will post 16.08 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date is Friday, June 28th. Humana’s payout ratio is 22.04%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft cut Humana from a “buy” rating to a “hold” rating and cut their price objective for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. Argus cut Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Barclays lowered their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Royal Bank of Canada reduced their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, The Goldman Sachs Group reduced their target price on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $424.50.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.32% of the stock is owned by insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.